Dipòsit Digital de Documents de la UAB 28 registres trobats  1 - 10següentfinal  anar al registre: La cerca s'ha fet en 0.01 segons. 
1.
10 p, 647.3 KB Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative / Giorgi Rossi, Paolo (Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy) ; Lebeau, Annette (Department of Pathology, University Medical Center Hamburg-Eppendorf) ; Canelo Aybar, Carlos (Institut d'Investigació Biomèdica Sant Pau) ; Saz-Parkinson, Zuleika (Instituto de Salud Carlos III) ; Quinn, Cecily (St. Vincent's University Hospital) ; Langendam, Miranda (Amsterdam UMC. University Medical Center) ; Mcgarrigle, Helen (Cardiff and Vale UHB - General Surgery, Cardiff, UK) ; Warman, Sue (Havyatt Lodge, Havyatt Road, Langford, North Somerset UK) ; Rigau, David (Institut d'Investigació Biomèdica Sant Pau) ; Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Broeders, Mireille (Dutch Expert Centre for Screening) ; Graewingholt, Axel (Radiologie am Theater, Paderborn, NRW Germany) ; Posso, Margarita (Institut Hospital del Mar d'Investigacions Mèdiques) ; Duffy, Stephen (Queen Mary University of London, Charterhouse Square. Centre for Cancer Prevention) ; Schünemann, Holger J. (McMaster University Health Sciences Centre, Hamilton. Michael G. DeGroote Cochrane Canada and McGRADE Centres; Department of Health Research Methods, Evidence and Impact) ; Universitat Autònoma de Barcelona
Predicting the risk of recurrence and response to chemotherapy in women with early breast cancer is crucial to optimise adjuvant treatment. Despite the common practice of using multigene tests to predict recurrence, existing recommendations are inconsistent. [...]
2021 - 10.1038/s41416-020-01247-z
British Journal of Cancer, Vol. 124 (february 2021) , p. 1503-1512  
2.
6 p, 754.7 KB Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial / Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ; André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ; Taieb, Julien (UMR-S 1147, INSERM) ; Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ; Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Hickish, Tamas (Royal Bournemouth Hospital and Bournemouth University. Department of Oncology) ; de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ; Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ; Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 - 10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317  
3.
4 p, 972.8 KB Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma : implications for biomarker-driven clinical trials / Montal, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Andreu-Oller, C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Bassaganyas, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Esteban-Fabró, Roger (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moran, Sebastian (Institut d'Investigació Biomèdica de Bellvitge) ; Montironi, C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moeini, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Pinyol, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Peix, J. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cabellos, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Villanueva, A. (Liver Cancer Program. Division of Liver Diseases. Icahn School of Medicine at Mount Sinai) ; Sia, D. (Liver Cancer Program. Division of Liver Diseases. Icahn School of Medicine at Mount Sinai) ; Mazzaferro, V. (University of Milan and Gastrointestinal Surgery and Liver Transplantation Unit. Fondazione IRCCS. Istituto Nazionale dei Tumori) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Llovet, J.M. (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. [...]
2019 - 10.1038/s41416-019-0513-7
British Journal of Cancer, Vol. 121 Núm. 4 (13 2019) , p. 340-343  
4.
6 p, 332.7 KB Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype / Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Tobeña, María (Institut d'Investigació Biomèdica Sant Pau) ; Fernández-Plana, Julen (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Virgili, Anna C. (Institut d'Investigació Biomèdica Sant Pau) ; Cirera, Lluís (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Riera, Pau (Institut d'Investigació Biomèdica Sant Pau) ; Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ; Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Patients harbouring the UGT1A1 *28/*28 genotype are at risk of severe toxicity with the standard irinotecan dose. However, this dose is considerably lower than the dose that can be tolerated by UGT1A1 *1/*1 and *1/*28 patients. [...]
2018 - 10.1038/s41416-018-0348-7
British Journal of Cancer, Vol. 120 (december 2018) , p. 190-195  
5.
15 p, 1.5 MB Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O· production in cancer cells / Cordani, Marco (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; Butera, Giovanna (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Dando, Ilaria (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Torrens-Mas, Margalida (Institut d'Investigació Sanitària de Palma) ; Butturini, Elena (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Pacchiana, Raffaella (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Oppici, Elisa (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Cavallini, Chiara (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ; Gasperini, Sara (Section of General Pathology, University of Verona. Department of Medicine) ; Tamassia, Nicola (Section of General Pathology, University of Verona. Department of Medicine) ; Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ; Coan, Michela (National Cancer Institute (Aviano, Itàlia)) ; Rossi, Davide (Institute of Oncology Research) ; Gaidano, Gianluca (University of Eastern Piedmont. Division of Hematology, Department of Translational Medicine) ; Caraglia, Michele (Department of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy) ; Mariotto, Sofia (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Spizzo, Riccardo (National Cancer Institute (Aviano, Itàlia)) ; Roca, Pilar (Institut d'Investigació Sanitària de Palma) ; Oliver, Jordi (Institut d'Investigació Sanitària de Palma) ; Scupoli, Maria Teresa (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ; Donadelli, Massimo (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Universitat Autònoma de Barcelona
The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function isoforms actively promote cancer malignancy. A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status. [...]
2018 - 10.1038/s41416-018-0288-2
British Journal of Cancer, Vol. 119 (october 2018) , p. 994-1008  
6.
7 p, 1.3 MB Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer / Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Pezet, Denis (Centre Hospitalier Universitaire) ; Deplanque, Gael (Hôpital Riviera-Chablais) ; Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ; Trojan, Jorg (Goethe University Medical Center) ; Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ; Kozloff, Mark (Ingalls Memorial Hospital) ; Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Smith, Claire (formerly of Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ; Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ; Blunt, Al (Advaxis, Inc) ; Benhadji, Karim A. (Eli Lilly and Company) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214  
7.
7 p, 549.5 KB Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma / Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary) ; Motzer, Robert J. (Memorial Sloan Kettering Cancer Center) ; Escudier, Bernard (Gustave Roussy) ; Pal, Sumanta (City of Hope National Medical Center) ; Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency) ; Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland) ; Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital) ; Rha, Sun Young (Yonsei Cancer Center. Severance Hospital) ; Park, Se Hoon (Samsung Medical Center) ; Geertsen, Poul F. (Copenhagen University. Herlev and Gentofte Hospital, Herlev Hospital) ; Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France) ; Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ; Suarez, Cristina (Vall d'Hebron Institut d'Oncologia) ; Markby, David W. (Exelixis, Inc) ; Arroyo, Alan (Exelixis, Inc) ; Dean, Mark (Exelixis, Inc) ; Choueiri, Toni K. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; George, Daniel (Duke University Medical Center) ; Universitat Autònoma de Barcelona
In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. [...]
2018 - 10.1038/s41416-018-0164-0
British Journal of Cancer, Vol. 119 (september 2018) , p. 663-669  
8.
8 p, 518.2 KB Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) / Solis-Hernandez, Mª Pilar (Hospital Universitario Central de Asturias) ; Fernandez del Valle, Ana (Hospital Universitario Central de Asturias. Radiology Department) ; Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Custodio, Ana (Hospital Universitario La Paz (Madrid)) ; Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Alonso Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ; Nuñez-Valdovino, Bárbara (Hospital Clinico Universidad de Chile (Santiago de Xile, Xile)) ; Sanchez Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia)) ; Matos, Ignacio (Hospital Universitari Vall d'Hebron) ; Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ; Lopez, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Viudez, Antonio (Complejo Hospitalario de Navarra) ; Izquierdo, Marta (Hospital Universitario Central de Asturias) ; Calvo-Temprano, David (Hospital Universitario Central de Asturias) ; Grande, Enrique (MD Anderson Cancer Center) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ; Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias) ; Universitat Autònoma de Barcelona ; Vall d'Hebron Institut d'Oncologiagia
The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. [...]
2019 - 10.1038/s41416-019-0558-7
British Journal of Cancer, Vol. 121 (september 2019) , p. 537-544  
9.
6 p, 374.8 KB A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients / Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Pericay, Carles (Parc Taulí Hospital Universitari) ; Valladares-Ayerbes, Manuel (Complejo Hospitalario Universitario de A Coruña) ; Bando, Inmaculada (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ; Safont, Maria Jose (Hospital General Universitario de Valencia) ; Gallego, Javier (Hospital General Universitario de Elche) ; Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ; Arrivi, Antonio (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ; Conde, Verónica (Hospital Universitario Virgen de las Nieves (Granada)) ; Ortiz, Maria José (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ; López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Alonso, Beatriz (Hospital Universitario de Canarias (La Laguna)) ; Ruiz de Mena, Inmaculada (Spanish Cooperative Group for the Treatment of Digestive Tumours) ; Díaz-Rubio, Eduardo (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Aranda, Enrique (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ; Universitat Autònoma de Barcelona
Targeted agents are standard treatment for RAS wild-type metastatic colorectal cancer in the first- and second-line settings. This phase 2 study determined the benefit of targeting the epidermal growth factor receptor (EGFR) with panitumumab plus irinotecan in irinotecan-refractory patients. [...]
2019 - 10.1038/s41416-019-0537-z
British Journal of Cancer, Vol. 121 (july 2019) , p. 378-383  
10.
10 p, 1.0 MB A systematic review and quality assessment of individualised breast cancer risk prediction models / Louro, Javier (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ; Posso, Margarita (Institut Hospital del Mar d'Investigacions Mèdiques) ; Hilton Boon, Michele (University of Glasgow) ; Román, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ; Domingo, Laia (Institut Hospital del Mar d'Investigacions Mèdiques) ; Castells, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Sala, María (Institut Hospital del Mar d'Investigacions Mèdiques)
Individualised breast cancer risk prediction models may be key for planning risk-based screening approaches. Our aim was to conduct a systematic review and quality assessment of these models addressed to women in the general population. [...]
2019 - 10.1038/s41416-019-0476-8
British Journal of Cancer, Vol. 121 (may 2019) , p. 76-85  

Dipòsit Digital de Documents de la UAB : 28 registres trobats   1 - 10següentfinal  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.